Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Clinical trial NCT02853331 · COMPLETED
Trial details
- NCT number
- NCT02853331
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-16
- Primary completion
- 2018-10-18
- Enrollment
- 861
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.